NLRP3 and peripheral arterial disease: This finding is contrary to Mishra et al., which showed the blockage of NLRP3 inflammasome activation and IL-1β release after inhibiting PAD activity with Cl-amidine in bone marrow-derived macrophages (BMDMs) [9].